Xenical Articles
EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri
20 February 2012
GlaxoSmithKline to shed OTC brands, including Alli, as US consumer group calls for the latter to be banned
18 April 2011
UK’s MHRA won’t take action on Roche’s Xenical marketing
30 September 2009
FDA eyes orlistat for potential liver problems, Chantix under scrutiny for skin reaction
5 June 2009
GSK France welcomes alli launch OK from EC
22 April 2009
EC approves GSK's OTC orlistat product alli
26 January 2009
Japan stock market week to Jan 19, 2009
26 January 2009
Taisho and GSK to develop orlistat in Japan
26 January 2009
EMEA approves GSK's OTC obesity drug
3 November 2008
UK's PMCPA names Roche in advertisements
8 September 2008
Roche's UK unit gets six-month ABPI ban
21 July 2008
Abbott comments on NICE obesity drug guidance
7 July 2008
Roche faces Xenical diet clinic probe
3 March 2008
UK obesity drug Rxs pass million, increasing eightfold over 1999
14 February 2008
UPDATE: 2007 NASSO conference hears encouraging data on GSK's alli, Orexigen's Contrave et al
29 October 2007
CHMP gives nod to GSK's orlistat
4 June 2007
Xenical boosts weight loss and cuts CV risk
30 April 2007
Roche 1st-qtr at top end of expectations
23 April 2007
GSK's orlistat 60mg gets FDA OK for OTC
19 February 2007
Xenical impresses in weight loss study
30 October 2006
Xenical improves glycemic control
18 September 2006
Roche's Xenical shows greater benefit in early responders
11 September 2006
Takeda starts Ph II trial of Alizyme's cetilistat
30 January 2006
Alizyme's cetilistat performs well in trials
19 December 2005
Xenical safe/effective in adolescents
20 June 2005
Roche grants GSK US marketing rights to OTC Xenical
18 April 2005
Japan stock market week to April 11
18 April 2005
Alizyme anti-obesity drug trials begin
14 February 2005
UK NICE delivering "up to a point," says study
8 November 2004
Alizyme to begin UK Phase IIb trial of ATL-962
11 October 2004
Sanofi-Aventis' Acomplia will have huge impact on obesity market
6 September 2004
Xenical effective in overweight teenagers
7 June 2004
Alizyme's loss climbs 2% for 2003
12 April 2004
EU approves lalbel extension for Roche's Xenical
29 March 2004
Roche acquires rights to Ipsen's BIM 51077
27 October 2003
Roche beats forecasts with pharma sales up 13% in first 9 months
27 October 2003
Singapore lifestyle drug spending booms
17 March 2003
Obesity: "unmet needs create huge potential"
17 March 2003
Alizyme ends enrollment in obesity trial
10 March 2003
Singapore first Asian market for Cialis
24 February 2003
New label claim for Roche's Xenical
29 July 2002
Europe OKs Xenical label change
22 July 2002
Alizyme gets OK for obesity drug trials in UK
24 June 2002
Xenical can help in diabetes management
24 June 2002
Study finds Xenical does well in real-world setting
10 June 2002
Drugs ordered on-line without prescription
20 May 2002
Fillip for Roche as three drugs get EU backing
25 March 2002
Fast-track MS drug plan for the UK
25 February 2002
Alizyme successfully completes Phase I program for ATL-962
7 January 2002
Alizyme successfully completes Phase I program for ATL-962
24 December 2001
NICE issues guidance on Reductil for obesity
17 October 2001
Xenical cuts drug use in obese type 2 diabetics
13 September 2001
Sales of Xenical rise as new trial data reported
3 July 2001
Canada: priority review for Xenical in diabetes
12 June 2001
Canada: priority review for Xenical in diabetes
8 June 2001
Knoll launches Reductil in UK
24 May 2001
Dip in 1st-qtr pharma sales at Roche
11 April 2001
Roche files Xenical sNDA for diabetes
22 March 2001
ABPI welcomes NICE decision on Xenical
13 March 2001
Net income leaps 50% at Roche in 2000, but pharma sales disappoint
28 February 2001
Stock Commentary - Europe
1 February 2001
US and Euro stock ratings "are full," says Commerzbank
31 January 2001
Alizyme sees positive Ph Ib data on ATL-962
16 January 2001
Roche names GSK's Abercrombie to heard N Amer pharma ops
12 January 2001
BASF excited about prospects for D2E7, as rumor mill talks of pharma
15 November 2000
New data show Xenical effective in treatment of diabetes
9 November 2000
Falling US sales for high-profile drugs
8 November 2000
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
